Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: A porcine model

Journal of Controlled Release

Volumn 160, Issue 2, 2012, Pages 382-387

  Szebeni, János ^a,b,f   Bedocs, Péter ^a,b,c   Urbanics, Rudolf ^b   Bünger, Rolf ^c   Rosivall, László ^a   Tóth, Miklós ^d   Barenholz, Yechezkel ^e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SeroScience Ltd   (Hungary)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY OF PHYSICAL EDUCATION   (Hungary)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

CARPA; Drug targeting; Hypersensitivity reactions; Innate immunity; Nanomedicines; Tolerance induction

Indexed keywords

CARPA; DRUG-TARGETING; HYPERSENSITIVITY REACTION; INNATE IMMUNITY; NANOMEDICINES;

CHEMOTHERAPY;

LIPOSOMES;

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXEBO; DOXORUBICIN; LIPOSOME; PLACEBO; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; COMPLEMENT ACTIVATION RELATED PSEUDOALLERGY; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; INFUSION RELATED REACTION; INNATE IMMUNITY; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; SINGLE DRUG DOSE; SWINE; TACHYPHYLAXIS; TREATMENT RESPONSE;

ANIMALS; COMPLEMENT ACTIVATION; DESENSITIZATION, IMMUNOLOGIC; DOXORUBICIN; DRUG CARRIERS; FEMALE; HYPERSENSITIVITY; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; PLACEBOS; POLYETHYLENE GLYCOLS; SWINE; TACHYPHYLAXIS;

EID: 84861669650     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.02.029     Document Type: Article

References (34)

1. Y. Barenholz Doxil - the first FDA-approved nano-drug: from an idea to product D. Peer, Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications 2012 Pan Stanford Publishing Pte. Ltd. Singapore 335 398
2. A. Gabizon, and F. Martin Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours Drugs 54 1997 15 21
3. A.A. Gabizon, and F.M. Muggia Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors M.C. Woodle, G. Storm, Long-Circulating Liposomes: Old Drugs, New Therapeutics 1998 Landes Bioscience Austin, TX 155 174
4. www.ClinicalTrials.gov 2012
5. Doxil, Package insert www.Doxil.com 2012
6. B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao, Z. Yehoshua, E. Libson, F.M. Muggia, and A. Gabizon Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J. Clin. Oncol. 13 1995 1777 1785
7. D.S. Alberts, and D.J. Garcia Safety aspects of pegylated liposomal doxorubicin in patients with cancer Drugs 54 Suppl. 4 1997 30 45
8. K.M. Skubitz, and A.P. Skubitz Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil) Anticancer Drugs 9 1998 45 50
9. O. Lyass, B. Uziely, R. Ben-Yosef, D. Tzemach, N.I. Heshing, M. Lotem, G. Brufman, and A.A. Gabizon Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Cancer 89 2000 1037 1047
10. A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N.M. Rafique, C.R. Alving, and F.M. Muggia Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions Ann. Oncol. 14 2003 1430 1437
11. J. Szebeni, B. Baranyi, S. Savay, L.U. Lutz, E. Jelezarova, R. Bunger, and C.R. Alving The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®) J. Liposome Res. 10 2000 347 361
12. J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, R. Bunger, P. Laverman, J.M. Metselaar, G. Storm, A. Chanan-Khan, L. Liebes, F.M. Muggia, R. Cohen, Y. Barenholz, and C.R. Alving Role of complement activation in hypersensitivity reactions to Doxil and HYNIC-PEG liposomes: experimental and clinical studies J. Liposome Res. 12 2002 165 172
13. J. Szebeni, P. Bedocs, Z. Rozsnyay, Z. Weiszhár, R. Urbanics, L. Rosivall, R. Cohen, O. Garbuzenko, G. Báthori, M. Tóth, R. Bünger, and Y. Barenholz Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome Nanomedicine NBM 8 2012 176 184
14. J. Szebeni, J.L. Fontana, N.M. Wassef, P.D. Mongan, D.S. Morse, D.E. Dobbins, G.L. Stahl, R. Bünger, and C.R. Alving Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99 1999 2302 2309
15. J. Szebeni Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents Crit. Rev. Ther. Drug Carrier Syst. 18 2001 567 606
16. J. Szebeni Complement activation-related pseudoallergy: mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents J. Szebeni, The Complement System: Novel Roles in Health and Disease 2004 Kluwer Boston, MA 399 440
17. J. Szebeni Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity Toxicology 216 2005 106 121
18. Y. Barenholz, and S. Amselem Quality control assays in the development and clinical use of liposome-based formulations G. Gregoriadis, Liposome Technology 2nd ed Liposome Preparation and Related Techniques. Vol. I 1993 CRC Press Boca Raton, FL 527 616
19. M. Schmidtgen, and M. Brandl Detection of lipopolysaccharides in phospholipids and liposomes using the limulus test J. Liposome Res. 5 1995 109 116
20. J. Szebeni, B. Baranyi, S. Savay, M. Bodo, D.S. Morse, M. Basta, G.L. Stahl, R. Bunger, and C.R. Alving Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction Am. J. Physiol. 279 2000 H1319 H1328
21. J. Szebeni, L. Baranyi, S. Sávay, M. Bodó, J. Milosevits, C.R. Alving, and R. Bünger Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function Am. J. Physiol. 290 2006 H1050 H1058
22. J. Szebeni, R. Bunger, L. Baranyi, P. Bedocs, M. Toth, L. Rosivall, Y. Barenholz, and C.R. Alving Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles J. Liposome Res. 17 2007 107 117
23. S.P. Kang, and M. Wasif Saif Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer: identification, prevention and management J. Support. Oncol. 5 2007 451 457
24. H.J. Lenz Management and preparedness for infusion and hypersensitivity reactions Oncologist 12 2007 601 609
25. W.H. Vogel Infusion reactions: diagnosis, assessment, and management Clin. J. Oncol. Nurs. 14 2010 E10 E21
26. J. Szebeni, F. Muggia, G. Gabizon, and Y. Barenholz Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention Adv. Drug Deliv. Rev. 63 2011 1020 1030
27. http://www.patientsville.com/medication/doxil18-side-effects.htm#reports 2012
28. O. Merkel, R. Urbanics, P. Bedocs, Z. Rozsnyay, L. Rosivall, M. Toth, T. Kissel, and J. Szebeni In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine- graft-poly(ethylene glycol) block copolymers Biomaterials 32 2011 4936 4942
29. A.W. Richter, and E. Kerblom Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors Int. Arch. Allergy Appl. Immunol. 74 1984 36 39
30. J. Szebeni, and Y. Barenholz Complement activation, immunogenicity, and immune suppression as potential side effects of lipsomes D. Peer, Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications 2012 Pan Stanford Publishing Pte. Ltd. Singapore 309 334
31. K. Andresen, J. Jörgensen, and J. Szebeni Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production FASEB J. 20 2006 2591 2593
32. G.C. Winkler Pulmonary intravascular macrophages in domestic animal species: review of structural and functional properties Am. J. Anat. 181 1988 217 234
33. A.E. Warner, and J.D. Brain The cell biology and pathogenic role of pulmonary intravascular macrophages Am. J. Physiol. 258 1990 L1 L12
34. M. Rao, S.W. Rothwell, and C.R. Alving Trafficking of liposomal antigens to the trans-Golgi complex in macrophages Methods Enzymol. 373 2003 16 33